Literature DB >> 19749795

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.

S Ueno1, H Tatetsu, H Hata, T Iino, H Niiro, K Akashi, D G Tenen, H Mitsuya, Y Okuno.   

Abstract

We earlier reported that PU.1 was downregulated in myeloma cell lines and myeloma cells in a subset of myeloma patients, and that conditional PU.1 expression in PU.1-negative myeloma cell lines, U266 and KMS12PE, induced growth arrest and apoptosis. To elucidate the molecular mechanisms of the growth arrest and apoptosis, we performed DNA microarray analyses to compare the difference in gene expression before and after PU.1 induction in U266 cells. Among cell cycle-related genes, cyclin A2, cyclin B1, CDK2 and CDK4 were downregulated and p21 was upregulated, although among apoptosis-related genes, tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) was found highly upregulated. When TRAIL was knocked down by small interference RNAs, apoptosis of PU-1-expressing cells was inhibited, suggesting that TRAIL has a critical role in PU.1-induced apoptosis in both U266 and KMS12PE myeloma cells. In both U266 and KMS12PE cells expressing PU.1, PU.1 directly bound to a region 30 bp downstream of the transcription start site of the TRAIL gene. Upregulation of PU.1-induced transactivation of the TRAIL promoter in reporter assays, and disruption of the PU.1-binding site in the TRAIL promoter eliminated this transactivation. Therefore, we conclude that PU.1 is capable of inducing apoptosis in certain myeloma cells by direct transactivation of TRAIL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19749795      PMCID: PMC2917647          DOI: 10.1038/onc.2009.263

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  Coordinate regulation of RAG1 and RAG2 by cell type-specific DNA elements 5' of RAG2.

Authors:  W Yu; Z Misulovin; H Suh; R R Hardy; M Jankovic; N Yannoutsos; M C Nussenzweig
Journal:  Science       Date:  1999-08-13       Impact factor: 47.728

2.  Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2.

Authors:  E M Coccia; N Del Russo; E Stellacci; R Orsatti; E Benedetti; G Marziali; J Hiscott; A Battistini
Journal:  Oncogene       Date:  1999-03-25       Impact factor: 9.867

3.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Vania Gelmetti; Francesco Marchesi; Andrea Viale; Lucia Altucci; Clara Nervi; Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

4.  Identification of TRAIL as an interferon regulatory factor 3 transcriptional target.

Authors:  Jessica R Kirshner; Alla Y Karpova; Maren Kops; Peter M Howley
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Potential autoregulation of transcription factor PU.1 by an upstream regulatory element.

Authors:  Yutaka Okuno; Gang Huang; Frank Rosenbauer; Erica K Evans; Hanna S Radomska; Hiromi Iwasaki; Koichi Akashi; Francoise Moreau-Gachelin; Youlin Li; Pu Zhang; Berthold Göttgens; Daniel G Tenen
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

6.  Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.

Authors:  Ulf Klein; Stefano Casola; Giorgio Cattoretti; Qiong Shen; Marie Lia; Tongwei Mo; Thomas Ludwig; Klaus Rajewsky; Riccardo Dalla-Favera
Journal:  Nat Immunol       Date:  2006-06-11       Impact factor: 25.606

7.  Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1.

Authors:  Frank Rosenbauer; Bronwyn M Owens; Li Yu; Joseph R Tumang; Ulrich Steidl; Jeffery L Kutok; Linda K Clayton; Katharina Wagner; Marina Scheller; Hiromi Iwasaki; Chunhui Liu; Björn Hackanson; Koichi Akashi; Achim Leutz; Thomas L Rothstein; Christoph Plass; Daniel G Tenen
Journal:  Nat Genet       Date:  2005-11-27       Impact factor: 38.330

8.  PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.

Authors:  Gang Huang; Pu Zhang; Hideyo Hirai; Shannon Elf; Xiaomei Yan; Zhao Chen; Steffen Koschmieder; Yutaka Okuno; Tajhal Dayaram; Joseph D Growney; Ramesh A Shivdasani; D Gary Gilliland; Nancy A Speck; Stephen D Nimer; Daniel G Tenen
Journal:  Nat Genet       Date:  2007-11-11       Impact factor: 38.330

9.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

10.  Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.

Authors:  Hiro Tatetsu; Shikiko Ueno; Hiroyuki Hata; Yasuhiro Yamada; Motohiro Takeya; Hiroaki Mitsuya; Daniel G Tenen; Yutaka Okuno
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

View more
  8 in total

1.  Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.

Authors:  H Goto; R Kariya; E Kudo; Y Okuno; K Ueda; H Katano; S Okada
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

2.  PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression.

Authors:  Aladin Haimovici; Magali Humbert; Elena A Federzoni; Deborah Shan-Krauer; Thomas Brunner; Steffen Frese; Thomas Kaufmann; Bruce E Torbett; Mario P Tschan
Journal:  Cell Death Differ       Date:  2017-03-31       Impact factor: 15.828

3.  PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.

Authors:  N Ueno; N Nishimura; S Ueno; S Endo; H Tatetsu; S Hirata; H Hata; M Matsuoka; H Mitsuya; Y Okuno
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

4.  NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

Authors:  D Gerloff; R Grundler; A A Wurm; D Bräuer-Hartmann; C Katzerke; J-U Hartmann; V Madan; C Müller-Tidow; J Duyster; D G Tenen; D Niederwieser; G Behre
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

5.  PU.1 is a major transcriptional activator of the tumour suppressor gene LIMD1.

Authors:  Daniel E Foxler; Victoria James; Samuel J Shelton; Thomas Q de A Vallim; Peter E Shaw; Tyson V Sharp
Journal:  FEBS Lett       Date:  2011-03-12       Impact factor: 4.124

6.  The transcription factor PU.1 regulates γδ T cell homeostasis.

Authors:  Rukhsana Jabeen; Hua-Chen Chang; Ritobrata Goswami; Stephen L Nutt; Mark H Kaplan
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

7.  Comprehensive Analysis of Immune Implications and Prognostic Value of SPI1 in Gastric Cancer.

Authors:  Jianfeng Huang; Wenzheng Chen; Zhigang Jie; Mengmeng Jiang
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

8.  PU.1 is a tumor suppressor for B cell malignancies.

Authors:  Yutaka Okuno; Hiromichi Yuki
Journal:  Oncotarget       Date:  2012-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.